Diamond-Blackfan anemia in adults: In pursuit of a common approach for a rare disease

IF 6.9 2区 医学 Q1 HEMATOLOGY Blood Reviews Pub Date : 2023-09-01 DOI:10.1016/j.blre.2023.101097
Deena Iskander , Noémi B.A. Roy , Elspeth Payne , Emma Drasar , Kelly Hennessy , Yvonne Harrington , Chrysi Christodoulidou , Anastasios Karadimitris , Leisa Batkin , Josu de la Fuente
{"title":"Diamond-Blackfan anemia in adults: In pursuit of a common approach for a rare disease","authors":"Deena Iskander ,&nbsp;Noémi B.A. Roy ,&nbsp;Elspeth Payne ,&nbsp;Emma Drasar ,&nbsp;Kelly Hennessy ,&nbsp;Yvonne Harrington ,&nbsp;Chrysi Christodoulidou ,&nbsp;Anastasios Karadimitris ,&nbsp;Leisa Batkin ,&nbsp;Josu de la Fuente","doi":"10.1016/j.blre.2023.101097","DOIUrl":null,"url":null,"abstract":"<div><p><span>Diamond-Blackfan anemia (DBA) is a rare bone marrow failure syndrome, usually caused by loss-of function variants in genes encoding </span>ribosomal proteins<span>. The hallmarks of DBA are anemia, congenital anomalies<span> and cancer predisposition. Although DBA usually presents in childhood, the prevalence in later life is increasing due to an expanding repertoire of implicated genes, improvements in genetic<span> diagnosis and increasing life expectancy. Adult patients uniquely suffer the manifestations of end-organ damage caused by the disease and its treatment, and transition to adulthood poses specific issues in disease management. To standardize and optimize care for this rare disease, in this review we provide updated guidance on the diagnosis and management of DBA, with a specific focus on older adolescents and adults. Recommendations are based upon published literature and our pooled clinical experience from three centres in the United Kingdom (U·K.). Uniquely we have also solicited and incorporated the views of affected families, represented by the independent patient organization, DBA U.K.</span></span></span></p></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":null,"pages":null},"PeriodicalIF":6.9000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0268960X23000589","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Diamond-Blackfan anemia (DBA) is a rare bone marrow failure syndrome, usually caused by loss-of function variants in genes encoding ribosomal proteins. The hallmarks of DBA are anemia, congenital anomalies and cancer predisposition. Although DBA usually presents in childhood, the prevalence in later life is increasing due to an expanding repertoire of implicated genes, improvements in genetic diagnosis and increasing life expectancy. Adult patients uniquely suffer the manifestations of end-organ damage caused by the disease and its treatment, and transition to adulthood poses specific issues in disease management. To standardize and optimize care for this rare disease, in this review we provide updated guidance on the diagnosis and management of DBA, with a specific focus on older adolescents and adults. Recommendations are based upon published literature and our pooled clinical experience from three centres in the United Kingdom (U·K.). Uniquely we have also solicited and incorporated the views of affected families, represented by the independent patient organization, DBA U.K.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
成人Diamond-Blackfan贫血:寻找治疗罕见疾病的常用方法
Diamond Blackfan贫血(DBA)是一种罕见的骨髓衰竭综合征,通常由编码核糖体蛋白的基因功能缺失引起。DBA的特征是贫血、先天畸形和癌症易感性。尽管DBA通常出现在儿童期,但由于相关基因库的扩大、遗传诊断的改进和预期寿命的延长,其在晚年的患病率正在增加。成年患者独特地遭受由疾病及其治疗引起的末端器官损伤的表现,向成年的过渡在疾病管理中提出了特定的问题。为了规范和优化这种罕见疾病的护理,在这篇综述中,我们提供了DBA诊断和管理的最新指导,特别关注老年青少年和成年人。建议基于已发表的文献和我们从英国三个中心收集的临床经验。独特的是,我们还征求并采纳了由独立患者组织英国DBA代表的受影响家庭的意见。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Blood Reviews
Blood Reviews 医学-血液学
CiteScore
13.80
自引率
1.40%
发文量
78
期刊介绍: Blood Reviews, a highly regarded international journal, serves as a vital information hub, offering comprehensive evaluations of clinical practices and research insights from esteemed experts. Specially commissioned, peer-reviewed articles authored by leading researchers and practitioners ensure extensive global coverage across all sub-specialties of hematology.
期刊最新文献
Corrigendum to "Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?"[BLOOD REVIEWS, 9 August 2024, https://doi.org/10.1016/j.blre.2024.101226]. Clinical applications of circulating tumor DNA in hematological malignancies: From past to the future Tailoring oral anticoagulant treatment in the era of multi-drug therapies for PAH and CTEPH. Ven the dose matters: Venetoclax dosing in the frontline treatment of AML. Editorial Board
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1